On September 26, 2019 Baxter International Inc. (NYSE: BAX), a global leader in clinical nutrition reported that it will present at the ESMO (Free ESMO Whitepaper) congress to be held in Barcelona from 27 September to 1 October, organizing the symposium "Early and effective nutritional therapy in GI cancer patients: an opportunity to improve outcome (Press release, Baxter International, SEP 26, 2019, View Source [SID1234539825])."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Approximately 50% of oncology patients in Europe are affected by malnutrition. While the rate of malnutrition is even higher for patients with gastrointestinal (GI) cancers real-world evidence suggests that only 23% of GI cancer patients have malnutrition diagnosed, due to the lack of appropriate nutritional screening.1 Approximately one quarter of all cancer patients die due to consequences of malnutrition, but cancer-related malnutrition goes undiagnosed in many patients.2

Seven out of ten patients experience feeding problems during cancer treatment, chemotherapy and radiotherapy, leaving them at serious risk of malnutrition and its associated problems.3

Early initiation of clinical nutrition therapy after cancer diagnosis allows to achieve the best possible patient outcomes, improvement of cancer care and optimisation of healthcare resources use.4,5 Parenteral nutrition is a life-sustaining therapy when oral and enteral nutrition are not possible.

1 Tlemsani C et al. (2018) Malnutrition in cancer patients: is a late diagnosis a missed opportunity to improve care? Ann Oncol 29: viii603-40.
2 Hu W-H et al. (2015). Nutr J 14: 91. Lee H et al. (2013) Clin Nutr Res 2: 12-8.
3 ECPC Nutrition Booklet, 2018.
4 Tlemsani C et al. (2018) Malnutrition in cancer patients: is a late diagnosis a missed opportunity to improve care? Ann Oncol 29: viii603-4
5 Goldwasser, F et al. Challenges and Opportunities in Clinical Nutrition in Oncology: Available Evidence, Real-World Practices and the Way Forward, 2018.

On September 26, 2019, XOMA (US) LLC (the "Company"), a wholly-owned subsidiary of XOMA Corporation, reported that entered into a royalty purchase agreement (the "Purchase Agreement") with Palo Biofarma, S.L. ("Palo"), a company organized and existing under the laws of Spain (Filing, 8-K, Xoma, SEP 26, 2019, View Source [SID1234539844]). Pursuant to the Purchase Agreement, the Company acquired the rights to potential royalty payments in low single digit percentages of aggregate Net Sales (as defined in the Purchase Agreement) associated with six drug candidates in various clinical development stages, targeting the adenosine pathway with potential applications in solid tumors, asthma/chronic obstructive pulmonary disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, lung cancer, psoriasis and nonalcoholic steatohepatitis and other indications (the "Licensed Products") that are being developed by Palo. Novartis Pharma AG is a development partner on one of the Licensed Products (the "Licensee") and such Licensed Product is being developed pursuant to a license agreement between Palo and the Licensee.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the Purchase Agreement, the Company will pay Palo $10 million (the "Payment") for the rights to potential royalty payments on future sales of the Licensed Products. The Company plans to partially finance the Payment by drawing a $5 million term loan under its Loan and Security Agreement with Silicon Valley Bank dated May 7, 2018, as amended on March 4, 2019, as previously filed as an exhibit to the Company’s Quarterly Reports on Form 10-Q for the three month period ending June 30, 2018 and the three month period ending March 31, 2019.

The Purchase Agreement also contains customary representations, warranties, covenants and indemnities. The Purchase Agreement will terminate six (6) months following the full satisfaction of any amounts due under any of the License Agreements (as defined in the Purchase Agreement) and receipt by the Company of all payments to which it is entitled under the Purchase Agreement.

The description of the Purchase Agreement contained herein does not purport to be complete, and is qualified in its entirety by reference to such Purchase Agreement, together with the exhibits thereto, a copy of which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the period ending September 30, 2019.

On September 26, 2019 OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing late-stage intratumoral cancer immunotherapies, reported that Daniel J. O’Connor, President and Chief Executive Officer of OncoSec, will present a company overview at the Cantor 2019 Global Healthcare Conference on Thursday, October 3, 2019, at 7:45 a.m. Eastern Time in New York, NY (Press release, OncoSec Medical, SEP 26, 2019, View Sourcenews/detail/2008/oncosec-to-present-at-the-cantor-2019-global-healthcare-conference" target="_blank" title="View Sourcenews/detail/2008/oncosec-to-present-at-the-cantor-2019-global-healthcare-conference" rel="nofollow">View Source [SID1234539809]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation will be available on the Investors section of OncoSec’s website at View Source, where it will be archived for approximately 30 days.

On September 26, 2019 AVEO Oncology (NASDAQ:AVEO) reported that Michael Bailey, president and chief executive officer, will present at the 2019 Cantor Fitzgerald Global Healthcare Conference in New York on Friday, October 4, 2019 at 10:05 a.m. Eastern Time (Press release, AVEO, SEP 26, 2019, View Source [SID1234539826]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the webcast will be archived for 30 days following the presentation date.

On September 26, 2019 Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS platform, reported that members of its senior leadership team will participate in three industry and investor conferences focused on gene editing and gene therapy in October (Press release, Precision Biosciences, SEP 26, 2019, View Source [SID1234539929]). Presentations will consist of corporate overviews and a panel discussion. Participation at the Jefferies Gene Therapy Summit will be limited to private meetings.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa
Date: October 2-4, 2019
Presentation Time: October 3, 4:15 p.m. PT
Panel Time: October 4, 9:45 a.m. PT
Location: Carlsbad, CA
Speaker: Michael Dombeck, Senior Vice President, Corporate Development

Chardan Genetic Medicines Conference
Date: October 7-8, 2019
Presentation Time: October 8, 8:30 a.m. ET
Location: New York, NY
Speaker: Matt Kane, Chief Executive Officer

Jefferies Gene Therapy Summit
Date: October 8, 2019
Location: New York, NY
Matt Kane, Chief Executive Officer (investor meetings)

A live audio webcast of the Chardan presentation will be available here (webcast link) and up-to-date details for each event can be found on the "Events & Presentations" page in the Investors section of the Precision BioSciences website (www.precisionbiosciences.com). A replay of the Chardan presentation will also be archived for 30 days on the Events & Presentations page.